Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer

Published:2019-09-01 Issue:5 Volume:34 Page:1116-1124
ISSN:1226-3303
Container-title:The Korean Journal of Internal Medicine
language:en
Short-container-title:Korean J Intern Med

Author:

Ock Chan-Young,Yoo Shin-Hye,Keam Bhumsuk,Kim Miso,Kim Tae Min,Jeon Yoon Kyung,Kim Dong-Wan,Chung Doo Hyun,Heo Dae Seog

Funder

Health Technology Assessment Programme

Ministry of Health and Welfare

Publisher

Korean Association of Internal Medicine

Link

http://kjim.org/upload/kjim-2018-011.pdf

Reference27 articles.

1. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

2. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

3. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

4. Treating ALK-positive lung cancer—early successes and future challenges

5. Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy;Medicine;2024-05-24

2. Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea;Thoracic Cancer;2024-01-03

3. Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience;Clinical Cancer Investigation Journal;2022

4. Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK + NSCLC : A multicenter retrospective analysis in China;Thoracic Cancer;2021-12

5. Different clinical features between patients with ROS1-positive and ALK-positive advanced non-small cell lung cancer;Journal of International Medical Research;2021-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3